Parthenolide Attenuates Experimental Autoimmune Prostatitis Through the Suppression of NLRP3 Inflammasome-Induced Pyroptosis by Facilitating Nrf2 Activation
The International Journal of Biochemistry & Cell Biology · 2026-11 · 107073
DOI: 10.1016/j.biocel.2026.107073 ↗Kurz gefasst
Fachartikel in der Zeitschrift The International Journal of Biochemistry & Cell Biology, 2026-11. Verfasst von Andong Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, the First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, Anhui, China; Institute of Urology…. Die Arbeit nennt 67 Literaturangaben.
Abstract (Originalsprache)
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a prevalent urological disorder characterized by persistent pelvic pain and prostatic inflammation, yet effective treatments are limited. This study investigated whether parthenolide (PTL) alleviates experimental autoimmune prostatitis (EAP) by activating Nrf2/HO-1 signalling and suppressing NLRP3 inflammasome-mediated pyroptosis. Male NOD EAP model mice were treated with PTL with or without the Nrf2 inhibitor ML385. The underlying cellular mechanisms were elucidated using LPS-stimulated RAW264.7 macrophages. PTL reduced prostatic inflammatory infiltration, pelvic mechanical allodynia, and the expression of circulating proinflammatory cytokines in EAP mice. PTL also decreased NLRP3, cleaved caspase-1, GSDMD-N, cleaved IL-1β, and IL-18 levels in prostate tissues and LPS-stimulated macrophages. Mechanistically, PTL promoted Nrf2 nuclear accumulation and increased HO-1 expression, accompanied by increased antioxidant capacity and reduced oxidative damage. PTL treatment was also associated with reduced nuclear HDAC1 levels and increased histone H3 acetylation. ML385 substantially reversed the effects of PTL on oxidative stress, pyroptosis-associated signalling, prostate inflammation, and pelvic pain. Collectively, these findings demonstrate that PTL attenuates EAP by activating Nrf2/HO-1 signalling and suppressing oxidative stress and NLRP3 inflammasome-mediated pyroptotic signalling, supporting the further evaluation of PTL as a candidate therapeutic strategy for CP/CPPS.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, the First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, Anhui, China; Institute of Urology, Anhui Medical University, Hefei, Anhui, China; Anhui Province Key La…
Zitieren
APA
Zhang, A., Feng, R., Wu, B., & Yang, C. (2026). Parthenolide Attenuates Experimental Autoimmune Prostatitis Through the Suppression of NLRP3 Inflammasome-Induced Pyroptosis by Facilitating Nrf2 Activation. The International Journal of Biochemistry & Cell Biology, 107073. https://doi.org/10.1016/j.biocel.2026.107073
Vancouver
Zhang A, Feng R, Wu B, Yang C. Parthenolide Attenuates Experimental Autoimmune Prostatitis Through the Suppression of NLRP3 Inflammasome-Induced Pyroptosis by Facilitating Nrf2 Activation. The International Journal of Biochemistry & Cell Biology. 2026:107073. doi:10.1016/j.biocel.2026.107073
BibTeX
@article{Zhang2026,
author = {Zhang, Andong and Feng, Rui and Wu, Bin and Yang, Cheng},
title = {Parthenolide Attenuates Experimental Autoimmune Prostatitis Through the Suppression of NLRP3 Inflammasome-Induced Pyroptosis by Facilitating Nrf2 Activation},
journal = {The International Journal of Biochemistry & Cell Biology},
year = {2026},
pages = {107073},
doi = {10.1016/j.biocel.2026.107073}
}
EUVIMED